These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15953827)

  • 21. Complex I and Parkinson's disease.
    Greenamyre JT; Sherer TB; Betarbet R; Panov AV
    IUBMB Life; 2001; 52(3-5):135-41. PubMed ID: 11798025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular pathways of neurodegeneration in Parkinson's disease.
    Dawson TM; Dawson VL
    Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxic effects of dopamine metabolism in Parkinson's disease.
    Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.
    Soreq L; Ben-Shaul Y; Israel Z; Bergman H; Soreq H
    Neurobiol Dis; 2012 Mar; 45(3):1018-30. PubMed ID: 22198569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
    Pavlou MAS; Pinho R; Paiva I; Outeiro TF
    Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiologic studies of environmental exposures in Parkinson's disease.
    Elbaz A; Tranchant C
    J Neurol Sci; 2007 Nov; 262(1-2):37-44. PubMed ID: 17673256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease.
    Xie W; Wan OW; Chung KK
    Biochim Biophys Acta; 2010 Nov; 1802(11):935-41. PubMed ID: 20674742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.
    Shannon KM; Keshavarzian A; Dodiya HB; Jakate S; Kordower JH
    Mov Disord; 2012 May; 27(6):716-9. PubMed ID: 22550057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease.
    Yu S; Chan P
    Essays Biochem; 2014; 56():125-35. PubMed ID: 25131591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
    Wu Q; Yang X; Zhang Y; Zhang L; Feng L
    Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein and Parkinson's disease.
    Recchia A; Debetto P; Negro A; Guidolin D; Skaper SD; Giusti P
    FASEB J; 2004 Apr; 18(6):617-26. PubMed ID: 15054084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress.
    Abdulwahid Arif I; Ahmad Khan H
    Toxicol Ind Health; 2010 Mar; 26(2):121-8. PubMed ID: 20207656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.